Is BPC-157 legal in 2026?
A dated, plain-English answer — and what a licensed clinician can prescribe today while BPC-157 waits on FDA rulemaking.
Last reviewed July 26, 2026 · Updated after every FDA action · Not legal or medical advice
Short answer
BPC-157 is not FDA-approved for any human use. It is not on the FDA's 503A Bulks List — the list that lets a licensed pharmacy compound a substance for patients.
In April 2026 the nominator withdrew BPC-157's nomination and the FDA updated a website table. FDA did not re-evaluate it and preserved its safety findings verbatim, so BPC-157 sits in no category at all — outside every enforcement-discretion policy. It is not the same as approval, and it did not authorize compounding.
On July 23, 2026, the FDA's advisory committee (PCAC) voted 8–6 to recommend BPC-157 for the 503A Bulks List — a recommendation, not approval, and not authorization to compound. It is still not on the list; placement requires the FDA to complete formal rulemaking, realistically into 2027. Until then there is no compliant way to prescribe injectable BPC-157 for human use, and any site selling it today is operating outside the regulated pathway.
The two signals, kept separate
We keep these two signals separate on purpose. The regulatory label and the plain-English verdict answer different questions — and collapsing them is how gray-market sites make a withdrawn nomination sound like "cleared to buy."
Why the answer isn't yes or no
"Legal" means three different things, and BPC-157 fails all three
Most of the confusion online comes from mixing these up. They're separate questions with separate answers.
"Is it FDA-approved?"
No. BPC-157 has never been approved by the FDA for any human indication. Approval means the FDA reviewed the drug for safety and effectiveness. That has not happened, and nothing in 2026 changed it.
"Can a pharmacy compound it?"
Not compliantly. A pharmacy needs one of three things: a USP monograph, status as a component of an FDA-approved drug, or a place on the 503A Bulks List. BPC-157 has none of them. That's what the July meeting is about.
"Is it banned?"
No — and this is the part vendors exploit. The April 2026 change was a withdrawn nomination recorded in a website table, not a rule and not a re-evaluation. It did not grant permission. "Not prohibited" and "authorized" are not the same thing, and the gap between them is exactly where the gray market sells.
What the FDA is actually weighing, and what each outcome would mean →
Where BPC-157 stands — and what's available today
Two signals, kept separate: the regulatory status, and what it means for you.
See the full tracker and the changelog →
Compounded, not FDA-approved. Compounded medications are prepared by a licensed pharmacy for an individual patient and are not reviewed by the FDA for safety, effectiveness, or manufacturing the way approved drugs are. They are not the same as brand-name products, and they're only appropriate when a licensed clinician determines FDA-approved options don't fit your situation.
What we'll do when the FDA acts
We update this page within a day of any FDA action and date every change, so you can check when we last looked. We won't market BPC-157 until a licensed clinician can prescribe it through a compliant pharmacy — whatever the committee recommends.
The July 2026 vote result, and what happens next →
Here's what a clinician can help with today
If you came here for recovery, energy, longevity or weight, you don't have to wait on a committee. There are compounded therapies a licensed clinician can prescribe today where they're clinically appropriate — matched to your goal, your health history and your state. Two minutes tells you what you're eligible for. Nothing to pay to find out.
Questions people ask
Is BPC-157 legal in 2026?
BPC-157 is not FDA-approved for any human use, and it is not on the FDA's 503A Bulks List that would let licensed pharmacies compound it. In April 2026 the nominator withdrew its nomination and the FDA updated a website table — not a rulemaking, and not authorization to compound. FDA did not re-evaluate BPC-157 and preserved its safety findings verbatim, so it now sits in no category at all, outside every FDA enforcement-discretion policy. On July 23, 2026 the PCAC voted to recommend it for the 503A Bulks List (tally reported as 8–6–1 as reported by trade press (FDA has posted no minutes, transcript or vote-results summary)), which is advisory: not approval, not authorization, and not availability. It is still not on the list; that requires FDA rulemaking, realistically into 2027, so there is no compliant prescribing pathway today.
Did the FDA ban BPC-157?
No. Coming off Category 2 is neither a ban nor approval, and here it happened because the nominator withdrew the nomination rather than because FDA reconsidered anything: FDA preserved the safety-risk description verbatim, and a substance in no category is outside every enforcement-discretion policy — a narrower position than Category 2, not a wider one. The July 2026 meeting produced a recommendation only; the FDA makes the final call afterward through a formal rulemaking process.
Can I buy BPC-157 from Peptos?
No. We publish education and a waitlist only. We won't market or facilitate a prescription for BPC-157 until a licensed clinician can prescribe it through a compliant pharmacy. If a site offers to ship you injectable BPC-157 for human use today, it's operating outside the regulated pathway — and the product quality is unverified.
What about sites selling BPC-157 as "research use only"?
Research-use-only products are sold for laboratory work, without a prescription, a clinician, or medical oversight. When a vendor sells an RUO vial and then supplies human dosing guidance, the label is doing legal work the product isn't. Independent testing of research peptides has repeatedly found underdosed, contaminated, or misidentified product. We break the distinction down in full on our peptide legality guide.
Why are CJC-1295 and Ipamorelin marked "not available"?
Neither is on the 503A list. CJC-1295's nomination was withdrawn, which leaves it in no FDA category and outside every enforcement-discretion policy; Ipamorelin acetate is withdrawn on the 503A side and still annotated Category 2 under FDA's 503B interim policy. We don't list them as available, and we treat any vendor presenting them as ready-to-order as a signal to look elsewhere.
What can a clinician prescribe right now?
Depending on your health history and your state, a licensed clinician may prescribe compounded semaglutide or tirzepatide, sermorelin, NAD+ and B12, among others. These are compounded and not FDA-approved. The eligibility check shows what applies to you before anyone charges you anything.